Scottsdale Interventional Forum 2025

1. Overview
The Scottsdale Interventional Forum 2025 provides an advanced clinical update on structural heart disease, complex coronary interventions, and the management of cardiogenic shock. The program focuses on transcatheter valve therapies, innovative PCI techniques, the integration of intravascular imaging, and mechanical circulatory support strategies to optimize patient outcomes in the modern cath lab.
Course Date: 2025
2. Learning Objectives

Evaluate and implement the latest transcatheter interventions for structural heart disease, including TAVR, M-TEER, and emerging tricuspid therapies.

Apply advanced techniques and intravascular imaging (IVUS) to optimize complex percutaneous coronary interventions (PCI), such as CTOs, bifurcations, and left main disease.

Assess the current evidence and clinical protocols for managing acute cardiogenic shock, utilizing mechanical circulatory support and shock team models.

Navigate complex decision-making in STEMI management, including the debate on complete versus culprit-only revascularization and the timing of mechanical unloading.

Formulate comprehensive management strategies for complex structural and coronary cases, addressing challenges like severe valvular disease with concomitant CAD and vascular access issues.

3. Target Audience

Best for interventional cardiologists and structural heart specialists who want advanced updates on TAVR, complex PCI, and cardiogenic shock management.

4. Topics

01 RCA ISR Management – Stent Boost and IVUS Inform DES Over DCB in Elderly Patient

02 Severe Valvular and Left Main CAD in Frail Patient – DK Crush PCI Strategy and Impella Support

03 Aortic Valve-in-Valve in Lotus Prosthesis – Technical Challenges and Key Lessons

04 Chronic Total Occlusion in RCA With Severe Obesity – Retrograde PCI Strategy and IVUS Guidance

05 Valve-in-Valve in Bicuspid AVR With Dacron Graft – Managing Fracture Limitations

06 CTO in RCA With Persistent Angina – Dual Guide Approach, IVUS Imaging, and Stenting

07 Presentation of a Case – Concomitant AF Ablation and LAA Occlusion

08 Severe MR in a 71-Year-Old – Valve-in-Valve-in-Ring Approach and Deployment Challenges

09 Women’s Heart Disease – Key Symptom Patterns and Early Detection

10 Examples of Escalating MCS in STEMI

11 Mechanical Complications of MI with Cardiogenic Shock – MitraClip Rescue

12 Vascular Access Challenges with MCS

13 Cut, Laser, Drill, and Shock

14 Massive Coronary Thrombosis- Treatment Algorithm and Creative Approaches

15 The Most Difficult Bifurcations- A Step-by-Step Algorithm

16 Approaches to Treating Complex Vein Graft Lesions (and the Native Vessels They Supply)

17 Mitral Transcatheter Edge-to-Edge Repair and Mandatory Mechanical Circulatory Support in Patients with Structural Shock

18 Novel Use of MitraClip to Treat Aortic Regurgitation

19 Intravascular Imaging is Now Class 1A in the European Guidelines – How Should US Interventionalists Respond

20 Leaflet and Septal Modification during ViV TMVR – Rationale, Tips, and Tricks

21 Patient Selectiong for Tricuspid Therapies

22 Optimal TEE and 3D-ICE for Efficient and Effective T-TEER and TTVR

23 Transcatheter Mitral and Tricuspid Valve in Valve Best Practices

24 The Next Pillar of Heart Failure Management – the GLP-1 Agonist Phenomenon

25 Aortic Stenosis and Coronary Artery Disease – A Case Presentation

26 Coronary Evaluation and Stenting Pre-TAVR – Neither Cath nor PCI Frequently Necessary

27 Echo Gradients Are Flawed – All BE and SE Valves Do Well!

28 The Transcatheter Valve Journey – Present and Future

29 TAV-in-SAV and TAV-in-TAV – ABCDs of the Pre-Procedural Evaluation

30 Pre TAVR – Cath and Aggressive PCI for All

31 The Data Are Clear – Self-Expanding Superior in Smaller Valves

32 Catheter Based Treatment for Valvular Heart Disease

33 Advances in Coronary Artery Disease Management

34 The Growing Field of Heart Failure Management

35 EVOQUE Tricuspid Valve Replacement

36 Strategies to Prevent Heart Disease

37 Managing Stable CAD in Severe Aortic Stenosis – Insights from NOTION and PCI Strategies

38 Mean Gradient with TEER – Why Higher Gradients Should be Tolerated

39 Optimal Pharmacologic Management Following LAAO

40 Left Atrial Appendage Occlusion – Current Advances, Remaining Challenges

41 M-TEER for Functional MR

42 Putting LAAO Clinical Trials in Perspective

43 How to Treat This 75-Year-Old with Severe Degenerative MR

44 Catheter-Based Therapies for Managing Aortic Insufficiencies

45 Spare the Blade – M-TEER Today!

46 The Data Are Favorable, but Can T-TEER Be Democratized

47 Mitral Debate – No Way – Surgical Repair Rules Today!

48 Understanding FDA T-TEER Trials – Are There Enough Pros

49 The Role of Transcatheter Tricuspid Valve Replacement – Unsuccessful TTEER with Giant Coaptaion Gap

50 CT Guidance in TMVR – Lessons Learned and Evolving Imaging Protocols

51 Tricuspid Regurgitation Impact on TAVR and M-TEER

52 Transcatheter Repair versus Mitral Valve Surgery for Secondary Mitral Regurgitation – Challenges in Trial Design and Interpre…

53 Should There Be Sex-Based Considerations in the Care of the AS Patient

54 Will T-TEER Evolve Similar to M-TEER – an Operators Perpsective

55 Upstream Treatment of AS – Early TAVR, Evolved, TAVR Unload

56 Back to the Basics – Are Exercise Right Heart Catheterizations Mandatory

57 CVD Jeopardy – Cath Lab & ICU Essentials – Arrhythmias, Shock, and Dissection Anticoagulation Pitfalls

58 The Evolution of HFrEF Therapies

59 The Emerging Role of Transcatheter Shunts

60 Evidence-Based Interventions Targeting Valvular Heart Disease in Heart Failure

61 ModulHeart, Aortix and the Novel Support Devices for Heart Management

62 Mea Culpa, Mea Culpa, Mea Maxima Culpa – STEMI Management

63 Left Atrial Coronary Sinus Shunt Case – Salvaging a Disaster

64 The Heartbreak of Substance Use

65 Contemporary Management of STEMISHOCK

66 Cardiac Biomarkers in Acute and Chronic Care

67 Spontaneous Coronary Artery Dissection – Women & Heart Disease

68 Equipoise – Whats That – We Did That Study Already

69 Structural Heart Disease – Evaluation, Management and Postop Care

70 Cryptogenic Stroke – Whats a PFO

71 Surgical vs Transcatheter Approaches in Functional Mitral Regurgitation – Short and Long-Term Data

72 Failure to Cross – Success Begins with Failure

73 Left Main Disease – Management Challenges and PCI vs CABG Decision-Making

74 Making the Cath Lab a Safer Environment – Advances in Radiation Safety

75 Top Coronary Trials of the Last Year – 2025 Update

76 Oh, How I Wish That Wouldn’t Have Happened

77 Will There Be New Indications for the Use of DCB in Coronary Intervention

78 CCTA in 2025 – Planning PCI

79 AMI With Cardiogenic Shock and RV Failure – Escalating to ECMO for Hemodynamic Rescue

80 Comprehensive Invasive Physiology Suite – From Diagnosis to Outcomes

81 STEMI vs. Cardiogenic Shock – Understanding the Data on Complete vs. Culprit-Only PCI

82 Expanding Indication for Intravascular Lithotripsy

83 Restore EF, Protect III, Protect IV – Where Is the Data Leading

84 Shock Outcomes in 2024 – Review of Recent Data and Where to Go from There

85 Acute Cardiogenic Shock Management

86 STEMI Management – Unloading Before Revascularization – Clinical Implications

87 Elective Multivessel CAD and the Evidence for Complete Revascularization

88 How Shock Teams Are Changing the Landscape of Cardiogenic Shock Management

89 Mechanical Circulatory Support for Cardiogenic Shock – Back to the Basics

90 Preventing Plaque Instability and MI – ACS Is the End, Not the Beginning

91 Arrhythmia Management – SVT, PAT, vs AF – Which One Is It

92 The Practice of Knuckle-ology – Mastering Subintimal Antegrade Revascularization

93 Pulmonary Embolism Management – Case Presentation and Current Guidelines

94 Another Great Save from the Once and Forever SCAI Prez – 2025 Cases

95 Coronary Microvascular Dysfunction – Case Presentation and Discussion

96 Optimizing PCI Results with IVUS – Trial Results, Evolving Guidelines

97 The Impact of Coronary Sinus Reducer on Refractory Angina and Microvascular Dysfunction

98 Management of Acutely Decompensated Systolic Heart Failure – What Happened to My Pump

99 Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

100 GLP-1 the Good and the Bad

101 Indications for a Pacemaker – Whats a Block

102 Vascular Complications – Cath Lab Digest

103 Mechanical Circulatory Support in Action

104 Acute Coronary Syndrome STEMI vs NSTEMI